{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2"},{"groupId":"OG001","value":"95.2"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"groupId":"OG004","value":"80.0"},{"groupId":"OG005","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"},{"groupId":"OG001","value":"66.7"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"62.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"title":"Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"45.5"},{"groupId":"OG002","value":"71.4"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7"},{"groupId":"OG001","value":"40.0"},{"groupId":"OG002","value":"60.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"},{"groupId":"OG001","value":"57.1"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"66.7"},{"groupId":"OG005","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"57.1"},{"groupId":"OG002","value":"75.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"100.0"},{"groupId":"OG005","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"Persistence is defined as a transgene count greater than or equal to the lower limit of detection (LLOD) of 5 copies per reaction. Data obtained after the start of a new anti-cancer therapy were excluded. qPCR = Quantitative polymerase chain reaction.","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"NUMBER","populationDescription":"All participants in the JCAR017 treated set with baseline and on-study JCAR017 transgene results.","reportingStatus":"POSTED","timeFrame":"At Day 29 and Months 2, 3, 6, 9, 12, 18, and 24 post JCAR017 infusion.","title":"Percent of Participants With Presence of JCAR017 Transgene in Peripheral Blood by qPCR","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}